Full-Time

Quality Operations Specialist 3

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

No salary listed

Albuquerque, NM, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor's degree (BS or BA) in a scientific or related field from a four-year accredited college or university
  • Minimum of five (5) years of progressively increasing responsibility in the pharmaceutical or biologics industry, with experience in validation activities, regulatory compliance, and/or quality
  • Must have relevant experience in change control, deviations, and CAPA
  • Demonstrated understanding of laboratory, manufacturing, packaging, regulatory affairs, compliance, and quality assurance requirements for biological and aseptic drug product manufacturing
  • Experience working with third-party contract manufacturing in the pharmaceutical industry (strongly preferred)
  • Must pass a background check
  • Must pass a drug screen
  • May be required to pass Occupational Health Screening
Responsibilities
  • Serve as a quality resource and approving authority in support of validation, change control, work orders, and other related documents as the quality approver
  • Provide quality compliance direction for validation and manufacturing activities
  • Serve as the quality liaison by providing compliance requirements for new product opportunities, including new equipment and technology
  • Direct process improvements and goals for Curia using current regulations and demonstrated best practices
  • Serve as a quality liaison between the site and customers or regulatory agencies during facility audits/inspections
  • Support effective and efficient continuous quality and cost improvement efforts
  • Read/interpret SOPs to ensure compliance
  • Maintain up to date trainings
  • Provide quality oversight and approval related to validation of processes, utilities, facilities, and equipment
  • Provide quality validation oversight to facility, utility, and equipment upgrades
  • Provide review and approval for qualification, validation, re-qualification, and re-validation documents for equipment and manufacturing process protocols, deviations, and final report
  • Collaborate with validations and project teams on the coordination and prioritization of validation activities
  • Provide QA oversight of the writing, updating, and maintaining of pertinent validation master plans for the facility
  • Provide QA oversight for the writing, updating, and maintaining of pertinent validation technical packages for product submissions
  • Communicate with clients regarding changes to facilities, processes, and procedures
  • Provide plant management with data and information appropriate to reduce the potential for regulatory action and assist in Curia productivity management
  • Keep plant management advised concerning agency, customer, and internal audit compliance commitments
  • Provide training and technical expertise on quality systems, especially related to facilities, validation, engineering and cGMPs
Desired Qualifications
  • Experience with validation activities, regulatory compliance, and/or quality (already in requirements)
  • Experience working with third-party contract manufacturing in the pharmaceutical industry (strongly preferred) (already in requirements)
  • Knowledge of current good manufacturing practices and regulatory expectations for biological and aseptic drug product manufacturing
  • Regulatory agency inspections experience
  • Automation and commissioning experience
  • Knowledge of quality systems such as document control change control deviation CAPA investigation trend analysis and CAPA
  • Understanding of validation master plans and validation technical packages for products and facilities

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$1.1B

Headquarters

Albany, New York

Founded

1991

Simplify Jobs

Simplify's Take

What believers are saying

  • Biologics segment expansion under Steve Lavezoli accelerates high-margin pharmaceutical outsourcing revenue growth.
  • Carterra partnership positions Curia to capture Pacific Northwest biotech demand in antibody discovery services.
  • Gerald Auer's CFO appointment signals M&A activity and potential strategic initiatives enhancing shareholder value.

What critics are saying

  • Pace Life Sciences acquisition of New Jersey lab erodes Curia's analytical testing capacity and revenue.
  • Larger CDMOs like Lonza and Catalent undercut Curia on biologics capacity, stealing biotech contracts.
  • FDA scrutiny on srRNA manufacturing defects from Replicate Bioscience Phase 1 triggers potential client exodus.

What makes Curia unique

  • Pioneer in self-replicating RNA manufacturing, demonstrated through Replicate Bioscience Phase 1 clinical trial support.
  • Integrated enzymatic doggybone DNA technology via Touchlight collaboration expands mRNA manufacturing competitive advantages.
  • End-to-end CDMO services from discovery through cGMP manufacturing differentiate Curia from specialized competitors.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Curia who can refer or advise you

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Carlyle Group
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb.com
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

PPI News Agency
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.